| Literature DB >> 18028488 |
Philip S Rosenberg1, Blanche P Alter, Daniel C Link, Steven Stein, Elin Rodger, Audrey A Bolyard, Andrew A Aprikyan, Mary A Bonilla, Yigal Dror, George Kannourakis, Peter E Newburger, Laurence A Boxer, David C Dale.
Abstract
Severe congenital neutropenia (SCN) is a heterogeneous bone marrow failure syndrome predisposing to myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML). We studied 82 North American and Australian SCN patients enrolled in the Severe Chronic Neutropenia International Registry who were on long-term treatment with granulocyte colony-stimulating factor and for whom the neutrophil elastase (ELA2) gene was sequenced. There was no significant difference in the risk of MDS/AML in patients with mutant versus wild-type ELA2: the respective cumulative incidences at 15 years were 36% and 25% (P = 0.96). Patients with either mutant or wild-type ELA2 should be followed closely for leukaemic transformation.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18028488 PMCID: PMC3143022 DOI: 10.1111/j.1365-2141.2007.06897.x
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998